Merck KGaA, Darmstadt, Germany , a leading science and technology company, today announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback